Why is OCUL down?
Down 48% in 3 months while the S&P 500 fell 10%.
- It filed a prospectus for an offering of shares on Sep 30, 2025.
−3Long-term trend
Down 48% in 3 months while the S&P 500 fell 10%.
−3Long-term trend
Follow OCUL's trial news. Pro members can get an alert when Ocular Therapeutix files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Sales down 10% on the year |
| Latest filing | 8-K, Nov 9 |
After its last 4 reports it closed +2.6% on average, higher 3 of 4 times.
About 8 quarters
Chief Business Officer Namrata Saroj sold 35,370 shares on Nov 5, under a planned sale. 24 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
OCUL is #241 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 241 |
Net income over four quarters: OCUL -$327M, LXRX -$62.4M, VIR -$185M, OLMA -$236M.
Expected to report Thu Feb 4, before the open (in 75 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $12.9M, 11% less than a year ago; a loss of $0.42 a share, from $0.38.
“Selling and marketing expenses were $15.7 million for the third quarter of 2026, compared with $13.1 million for the comparable quarter of 2025, reflecting an increase in personnel and pre-commercial investments to prepare for a potential AXPAXLI wet AMD launch.”
OCUL's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“General and administrative expenses were $18.8 million for the third quarter of 2026, compared with $16.0 million for the comparable quarter of 2025 reflecting increased personnel costs and additional infrastructure to support an increased scope of clinical trials and manufacturing expansion.”
From its results filing (SEC filing · Nov 9)
Sales grew 0.3% a year over 3 years, fiscal 2022 to 2025.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -5.2% | +3.9% | -5.8% |
| Aug 3, 2026 | +1.4% | +2.8% | +12.5% |
| May 5, 2026 | -4.4% | -0.6% | -5.0% |
Sales grew in six of the last seven years, to $52M in 2025. It lost money in each of the eight years.
RSI 30.6, MACD below signal, below both averages. Not scored.
One insider sold $11K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: OCUL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
OCUL scores -8 today, which Breakaway calls Poor. It is #241 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 48% in 3 months while the S&P 500 fell 10%. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
OCUL scores -8 today, which Breakaway calls Poor (below zero). That is #241 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OCUL's -8.
One insider sold $11K across 1 filing in the last 6 months. No open-market buys on record. The newest is Donald Notman, Chief Operating Officer, who sold $11K on Aug 31.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.